Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-β type I receptor inhibitor

Cancer Science

Volumn 101, Issue 10, 2010, Pages 2207-2213

  Taniguchi, Yukimi ^a   Kawano, Kumi ^a   Minowa, Takuya ^a   Sugino, Takashi ^b   Shimojo, Yuki ^a   Maitani, Yoshie ^a  

^a HOSHI UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

A 83 01; ANTINEOPLASTIC AGENT; FOLATE LINKED LIPOSOMAL DOXORUBICIN; LY 364947; UNCLASSIFIED DRUG; A-83-01; DOXORUBICIN; FOLIC ACID; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; TGF-BETA TYPE I RECEPTOR; THIOCARBAMIC ACID DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HISTOLOGY; LUNG CARCINOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG POTENTIATION; NEOPLASMS, EXPERIMENTAL; TISSUE DISTRIBUTION; VASCULARIZATION;

ANIMALS; DOXORUBICIN; DRUG SYNERGISM; FEMALE; FOLIC ACID; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; THIOCARBAMATES; TISSUE DISTRIBUTION;

EID: 77957039960     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01646.x     Document Type: Article

References (24)

1. Weitman SD, Lark RH, Coney LR. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992, 52:3396-401.
2. Elnakat H, Ratnam M. Distribution functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004, 56:1067-84.
3. Wang H, Ross JF, Ratnam M. Structure and regulation of a polymorphic gene encoding folate receptor type gamma/gamma. Nucleic Acids Res 1998, 26:2132-42.
4. Ross JF, Wang H, Behm FG. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999, 85:348-57.
5. Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 1999, 8:775-82.
6. Shen F, Ross JF, Wang X, Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 1994, 33:1209-15.
7. Gabizon A, Horowitz AT, Goren D. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem 1999, 10:289-98.
8. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 2003, 9:6551-9.
9. Pan XQ, Wang H, Lee RJ. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res 2003, 20:417-22.
10. Zhao XB, Lee RJ. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv Drug Deliv Rev 2004, 56:1193-204.
11. Yamada A, Taniguchi Y, Kawano K, Honda T, Hattori Y, Maitani Y. Design of folate-linked liposomal Doxorubicin to its antitumor effect in mice. Clin Cancer Res 2008, 14:8161-8.
12. Kano MR, Bae Y, Iwata C. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci USA 2007, 104:3460-5.
13. Tojo M, Hamashima Y, Hanyu A. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci 2005, 96:791-800.
14. Li HY, Wang Y, Heap CR. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. J Med Chem 2006, 49:2138-42.
15. Tsekos NV, Zhang F, Merkle H, Nagayama M, Iadecola C, Kim SG. Quantitative measurements of cerebral blood flow in rats using the FAIR technique: correlation with previous iodoantipyrine autoradiographic studies. Magn Reson Med 1998, 39:564-73.
16. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007, 96:189-95.
17. Minowa T, Kawano K, Kuribayasi H. Changes in tumor microenvironment following TGF-beta type I receptor inhibitor treatment observed by diffusion and dynamic contrast-enhanced magnetic resonance imaging. Br J Cancer 2009, 101:1884-90.
18. Uster PS, Allen TM, Daniel BE, Mendez CJ, Newman MS, Zhu GZ. Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett 1996, 386:243-6.
19. Lee RJ, Wang S, Turk MJ, Low PS. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci Rep 1998, 18:69-78.
20. Bradley DP, Tessier JJ, Lacey T. Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. Magn Reson Imaging 2009, 27:377-84.
21. Matsushita Y, Iguchi H, Kiyosaki T. A high performance liquid chromatographic method of analysis of 4'-O-tetrahydropyranyladriamycin and their metabolites in biological samples. J Antibiot (Tokyo) 1983, 36:880-6.
22. Kano MR, Komuta Y, Iwata C. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci 2008, 100:173-80.
23. Gass A, Niendorf T, Hirsch JG. Acute and chronic changes of the apparent diffusion coefficient in neurological disorders--biophysical mechanisms and possible underlying histopathology. J Neurol Sci 2001, 186(Suppl 1):S15-23.
24. Turetschek K, Preda A, Novikov V. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 2004, 20:138-44.